Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

165.11 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Proposed Public Offering of Common Stock
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Releases Inaugural ESG Report
From Guardant Health, Inc.
Via Business Wire
News headline image
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
News headline image
Guardant Health Reports First Quarter 2023 Financial Results
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces Additions to Leadership Team
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
From Guardant Health, Inc.
Via Business Wire
News headline image
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
News headline image
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
From Guardant Health, Inc.
Via Business Wire
News headline image
Musa Tariq Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Participate in Upcoming March Investor Conferences
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
From Guardant Health Inc.
Via Business Wire
News headline image
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.